Genenta Science SpA ADR (GNTA NASDAQ) stock market data APIs
$0.7324
0(0%)
as of May 1, 2026
Try our APIs with
free plan!
Genenta Science SpA ADR Financial Data Overview
Price chart is built with
Anychart
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Prev. Close
0.7324
Open
0.7336
High
0.7473
Low
0.6718
52 wk Range
0.59-6.2
Market Cap
17 221 K
Shares Outstanding
23 591 K
EPS
-0.2
Beta
0.731
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Genenta Science SpA ADR data using free add-ons & libraries
Get Genenta Science SpA ADR Fundamental Data
Genenta Science SpA ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -6 575 658
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-10
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Genenta Science SpA ADR News
New
Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic ar...
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian...
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italia...
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business
Genenta Science SPA (NASDAQ:GNTA) is among the best Italian stocks to buy in 2026. Genenta Science SPA (NASDAQ:GNTA) will hold an extraordinary shareholders meeting on March 26. This comes on the back...
Get Genenta Science SpA ADR fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
